Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ad26.ZEBOV and MVA-BN-Filo in EBOVAC-Salone Control Participants
NCT05284097Phase 2Completed
- Sponsor
- London School of Hygiene & Tropical Medicine
- Start
- Sep 2022
- Primary completion
- Mar 2023
- Modality
- Viral Vector Vaccines, DNA Vaccines
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of zabdeno and Mvabea in Ebola virus disease (EVD), sponsored by London School of Hygiene & Tropical Medicine. Primary endpoints: Incidence of solicited adverse events, Incidence of unsolicited serious adverse events and 1 more. Started Sep 2022; status: completed.
02
Drugs
zabdenoMvabea
03
Conditions
Ebola virus disease (EVD)
Beyond the preview
Go deeper on NCT05284097.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05284097.